Teladoc's growth and profitability challenges continue amid rising competition. Learn why TDOC stock remains under pressure ...
Hims & Hers (NYSE: HIMS) has been on a wild journey over the past year as GLP-1s drive both big gains and big losses for the ...
Hosted on MSN21h
Citigroup Downgrades Hims & Hers Health (HIMS)Fintel reports that on January 10, 2025, Citigroup downgraded their outlook for Hims & Hers Health (NYSE:HIMS) from Neutral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback